Autres langues Suven Life Sciences Limited

Actions

SUVEN

INE495B01038

Marché Fermé - Bombay S.E. Autres places de cotation 12:00:50 02/05/2024			Varia. 5j.	Varia. 1 janv.
112,6 ^INR	+2,09 %		+5,00 %	+39,60 %

15/04	Suven Life Sciences présentera les résultats positifs de la phase 2 sur le samelisant (SUVN-G3031) lors de la réunion annuelle 2024 de l'American Academy of Neurology (AAN), à Denver, aux États-Unis.	CI
06/02	Suven Life Sciences annonce la randomisation du premier patient de l'étude clinique de phase 2 de Ropanicant (SUVN-911) pour le traitement du trouble dépressif majeur modéré à sévère aux États-Unis	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	15/04
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	06/02
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	30/01
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	30/01
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	04/11
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant	30/10/23
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	30/10/23
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3	24/10/23
Suven Pharma Appoints New Board and Management Team	30/09/23
Suven Pharma Appoints Sudhir Kumar Singh as CEO	30/09/23
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/08/23
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.	17/07/23
Suven Life Sciences : Form MGT-7 FY 2022-23	15/07/23
Suven Life Sciences : Annual Report FY 2022-23 (Book)	12/07/23
Suven Life Sciences : Annual Report 2022-2023	12/07/23
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting	05/06/23
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)	03/06/23
Suven Life Sciences : June 01, 2023Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA	01/06/23
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada	01/06/23
Suven Life Sciences : Schedule of Conference Call for Investors on May 26, 2023	19/05/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Suven Life Sciences Limited

Actions

SUVEN

INE495B01038

Autres langues

Filtres